Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$5.78 - $7.33 $2,155 - $2,734
373 Added 128.62%
663 $4,000
Q4 2023

Feb 14, 2024

SELL
$3.6 - $7.15 $5,468 - $10,860
-1,519 Reduced 83.97%
290 $2,000
Q2 2023

Aug 10, 2023

BUY
$5.19 - $8.07 $9,388 - $14,598
1,809 New
1,809 $12,000
Q4 2022

Jun 14, 2023

BUY
$5.8 - $8.98 $10,950 - $16,954
1,888 New
1,888 $12.3 Million
Q3 2022

Jun 14, 2023

BUY
$7.55 - $11.25 $14,367 - $21,408
1,903 New
1,903 $16 Million
Q2 2022

Jun 20, 2023

BUY
$6.8 - $14.23 $12,940 - $27,079
1,903 New
1,903 $14.4 Million
Q1 2022

Jun 20, 2023

BUY
$13.42 - $23.38 $25,538 - $44,492
1,903 New
1,903 $26.4 Million
Q4 2021

Jun 21, 2023

BUY
$12.78 - $23.74 $95,057 - $176,578
7,438 New
7,438 $177 Million
Q3 2021

Jun 21, 2023

BUY
$11.73 - $16.08 $87,247 - $119,603
7,438 New
7,438 $98 Million
Q1 2021

Jun 26, 2023

BUY
$13.84 - $17.8 $83,621 - $107,547
6,042 New
6,042 $87.2 Million
Q4 2020

Jun 22, 2023

BUY
$12.4 - $17.6 $90,792 - $128,867
7,322 New
7,322 $111 Million
Q3 2020

Jun 26, 2023

BUY
$11.59 - $14.93 $84,861 - $109,317
7,322 New
7,322 $96.9 Million
Q2 2020

Jun 26, 2023

BUY
$11.79 - $15.97 $86,326 - $116,932
7,322 New
7,322 $91.7 Million
Q1 2020

Jul 12, 2023

BUY
$9.31 - $21.24 $51,009 - $116,373
5,479 New
5,479 $73.6 Million
Q4 2019

Jul 12, 2023

BUY
$13.91 - $21.48 $76,212 - $117,688
5,479 New
5,479 $110 Million
Q3 2019

Jul 12, 2023

BUY
$15.84 - $30.01 $86,787 - $164,424
5,479 New
5,479 $87.4 Million
Q2 2019

Jul 12, 2023

BUY
$17.38 - $26.88 $82,050 - $126,900
4,721 New
4,721 $127 Million
Q1 2019

Jul 13, 2023

BUY
$9.2 - $21.21 $43,433 - $100,132
4,721 New
4,721 $81.3 Million

Others Institutions Holding MGTX

About MeiraGTx Holdings plc


  • Ticker MGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,010,700
  • Market Cap $292M
  • Description
  • MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative dise...
More about MGTX
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.